Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic AL amyloidosis: current approach and future direction.
Bou Zerdan M, Nasr L, Khalid F, Allam S, Bouferraa Y, Batool S, Tayyeb M, Adroja S, Mammadii M, Anwer F, Raza S, Chaulagain CP. Bou Zerdan M, et al. Among authors: anwer f. Oncotarget. 2023 Apr 26;14:384-394. doi: 10.18632/oncotarget.28415. Oncotarget. 2023. PMID: 37185672 Free PMC article. Review.
Treatment of relapsed multiple myeloma: Evidence-based recommendations.
Durer C, Durer S, Lee S, Chakraborty R, Malik MN, Rafae A, Zar MA, Kamal A, Rosko N, Samaras C, Valent J, Chaulagain C, Anwer F. Durer C, et al. Among authors: anwer f. Blood Rev. 2020 Jan;39:100616. doi: 10.1016/j.blre.2019.100616. Epub 2019 Aug 31. Blood Rev. 2020. PMID: 31500848 Review.
Efficacy and Safety of Recombinant Thrombomodulin for the Prophylaxis of Veno-Occlusive Complication in Allogeneiccit Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Kashyap R, Anwer F, Iqbal MA, Khalid F, Khan A, Ali MA, Anwar MY, Chaudhary A, Jaan A. Kashyap R, et al. Among authors: anwer f. Hematol Oncol Stem Cell Ther. 2023 Jan 17;16(2):93-101. doi: 10.1016/j.hemonc.2021.09.002. Hematol Oncol Stem Cell Ther. 2023. PMID: 34655527 Review.
Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients.
Rafae A, Ehsan H, Wahab A, Khan SI, Khan I, Ashraf S, Ali S, Khalid F, Neupane K, Valent J, Khouri J, Samaras C, Mazzoni S, Anwer F. Rafae A, et al. Among authors: anwer f. Crit Rev Oncol Hematol. 2022 Aug;176:103744. doi: 10.1016/j.critrevonc.2022.103744. Epub 2022 Jun 15. Crit Rev Oncol Hematol. 2022. PMID: 35717005 Review.
Advancements and future trends of immunotherapy in light-chain amyloidosis.
Mahadevia H, Ponvilawan B, Sharma P, Al-Obaidi A, Qasim H, Koyi J, Anwer F, Raza S. Mahadevia H, et al. Among authors: anwer f. Crit Rev Oncol Hematol. 2023 Mar;183:103917. doi: 10.1016/j.critrevonc.2023.103917. Epub 2023 Jan 22. Crit Rev Oncol Hematol. 2023. PMID: 36696931 Review.
On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone.
Hubben A, Dima D, Atieh T, Chaulagain C, Faiman B, Ferraro C, Mazzoni S, Williams L, Samaras C, Valent J, Sauter C, Anwer F, Khouri J. Hubben A, et al. Among authors: anwer f. Bone Marrow Transplant. 2023 May;58(5):610-612. doi: 10.1038/s41409-023-01938-0. Epub 2023 Feb 24. Bone Marrow Transplant. 2023. PMID: 36828957 Free PMC article. No abstract available.
213 results